Molecular pathogenesis of malignant mesothelioma

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1413-1419

  Sekido, Yoshitaka ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MAMMALIAN TARGET OF RAPAMYCIN; MERLIN; NEUROFIBROMATOSIS TYPE 2 PROTEIN; PROTEIN; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANGIOGENESIS; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME DAMAGE; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; ENDOTHELIUM CELL; FIBROBLAST; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DAMAGE; GENETIC SUSCEPTIBILITY; HISTONE MODIFICATION; HUMAN; INFLAMMATION; MACROPHAGE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE REPAIR; TUMOR SUPPRESSOR GENE;

ASBESTOS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENES, P16; HUMANS; MESOTHELIOMA; NEUROFIBROMIN 2; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84880273681     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt166     Document Type: Article

References (73)

1. Robinson, B.W. et al. (2005) Advances in malignant mesothelioma. N. Engl. J. Med., 353, 1591-1603.
2. Tsao, A.S. et al. (2009) Malignant pleural mesothelioma. J. Clin. Oncol., 27, 2081-2090.
3. Husain, A.N. et al. (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med., 133, 1317-1331.
4. Vogelzang, N.J. et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol., 21, 2636-2644.
5. Jakobsen, J.N. et al. (2011) Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother. Pharmacol., 68, 1-15.
6. Jean, D. et al. (2012) Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch. Pathol. Lab. Med., 136, 277-293.
7. Pass, H.I. et al. (2004) Malignant pleural mesothelioma. Curr. Probl. Cancer, 28, 93-174.
8. Liu, W. et al. (2000) Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage, and apoptosis in mesothelial cells. Am. J. Respir. Cell Mol. Biol., 23, 371-378.
9. Heintz, N.H. et al. (2010) Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am. J. Respir. Cell Mol. Biol., 42, 133-139.
10. Toyokuni, S. (2009) Mechanisms of asbestos-induced carcinogenesis. Nagoya J. Med. Sci., 71, 1-10.
11. Yang, H. et al. (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestosinduced oncogenesis. Proc. Natl Acad. Sci. USA, 103, 10397-10402.
12. Yang, H. et al. (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc. Natl Acad. Sci. USA, 107, 12611-12616.
13. Toumpanakis, D. et al. (2011) DNA repair systems in malignant mesothelioma. Cancer Lett., 312, 143-149.
14. Røe, O.D. et al. (2010) Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer, 67, 57-68.
15. Donaldson, K. et al. (2010) Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part. Fibre Toxicol., 7, 5.
16. Ryman-Rasmussen, J.P. et al. (2009) Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat. Nanotechnol., 4, 747-751.
17. Nagai, H. et al. (2011) Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. Proc. Natl Acad. Sci. USA, 108, E1330-E1338.
18. Brevet, M. et al. (2011) Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J. Thorac. Oncol., 6, 864-874.
19. Laurie, S.A. et al. (2011) Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. J. Thorac. Oncol., 6, 1950-1954.
20. Dubey, S. et al. (2010) A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J. Thorac. Oncol., 5, 1655-1661.
21. Hartman, M.L. et al. (2010) Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J. Thorac. Cardiovasc. Surg., 139, 1233-1240.
22. Barbone, D. et al. (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J. Biol. Chem., 283, 13021-13030.
23. Varghese, S. et al. (2011) Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer, 117, 361-371.
24. Menges, C.W. et al. (2010) A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer, 1, 493-505.
25. Garland, L.L. et al. (2011) Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J. Thorac. Oncol., 6, 1938-1945.
26. Campbell, N.P. et al. (2012) Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer, 78, 76-80.
27. Musti, M. et al. (2006) Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet. Cytogenet., 170, 9-15.
28. Xio, S. et al. (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene, 11, 511-515.
29. Illei, P.B. et al. (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res., 9, 2108-2113.
30. Wu, D. et al. (2013) Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am. J. Clin. Pathol., 139, 39-46.
31. Takeda, M. et al. (2012) Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. J. Clin. Pathol., 65, 77-82.
32. Chiosea, S. et al. (2008) Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod. Pathol., 21, 742-747.
33. Onofre, F.B. et al. (2008) 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNAICM, and AgNOR analysis. Cancer, 114, 204-215.
34. Matsumoto, S. et al. (2013) Morphology of 9p21 homozygous deletionpositive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol. doi:10.1002/cncy.21269.
35. Ivanov, S.V. et al. (2010) Pro-tumorigenic effects of miR-31 loss in mesothelioma. J. Biol. Chem., 285, 22809-22817.
36. Bott, M. et al. (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet., 43, 668-672.
37. Thurneysen, C. et al. (2009) Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer, 64, 140-147.
38. Cheng, J.Q. et al. (1999) Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a twohit mechanism of NF2 inactivation. Genes. Chromosomes Cancer, 24, 238-242.
39. Murakami, H. et al. (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res., 71, 873-883.
40. Yoshikawa, Y. et al. (2012) Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci., 103, 868-874.
41. Altomare, D.A. et al. (2009) Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc. Natl Acad. Sci. USA, 106, 3420-3425.
42. Altomare, D.A. et al. (2011) Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One, 6, e18828.
43. Hu, Q. et al. (2010) Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab. Invest., 90, 360-373.
44. Witowski, J. et al. (2008) New insights into the biology of peritoneal mesothelial cells: the roles of epithelial-to-mesenchymal transition and cellular senescence. Nephron. Exp. Nephrol., 108, e69-e73.
45. Sekido, Y. et al. (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res., 55,1227-1231.
46. Bianchi, A.B. et al. (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA, 92, 10854-10858.
47. Morrow, K.A. et al. (2012) Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim. Biophys. Acta, 1826, 400-406.
48. Guled, M. et al. (2009) CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes. Chromosomes Cancer, 48, 615-623.
49. Altomare, D.A. et al. (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res., 65, 8090-8095.
50. Jongsma, J. et al. (2008) A conditional mouse model for malignant mesothelioma. Cancer Cell, 13, 261-271.
51. Li, W. et al. (2010) Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell, 140, 477-490.
52. Laplante, M. et al. (2012) mTOR signaling in growth control and disease. Cell, 149, 274-293.
53. López-Lago, M.A. et al. (2009) Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol., 29, 4235-4249.
54. James, M.F. et al. (2009) NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell. Biol., 29, 4250-4261.
55. Pan, D. (2010) The hippo signaling pathway in development and cancer. Dev. Cell, 19, 491-505.
56. Yokoyama, T. et al. (2008) YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis, 29, 2139-2146.
57. Mizuno, T. et al. (2012) YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene, 31, 5117-5122.
58. Fujii, M. et al. (2012) TGF-ß synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med., 209, 479-494.
59. Eletr, Z.M. et al. (2011) An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem. Biophys., 60, 3-11.
60. Testa, J.R. et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet., 43, 1022-1025.
61. Harbour, J.W. et al. (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science, 330, 1410-1413.
62. Wiesner, T. et al. (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet., 43, 1018-1021.
63. Peña-Llopis, S. et al. (2012) BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet., 44, 751-759.
64. Fischer, J.R. et al. (2006) Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer, 54, 109-116.
65. Christensen, B.C. et al. (2009) Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res., 69, 227-234.
66. Goto, Y. et al. (2009) Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res., 69, 9073-9082.
67. Christensen, B.C. et al. (2010) Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res., 70, 5686-5694.
68. Kemp, C.D. et al. (2012) Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin. Cancer Res., 18, 77-90.
69. Busacca, S. et al. (2010) MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am. J. Respir. Cell Mol. Biol., 42, 312-319.
70. Pass, H.I. et al. (2010) hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res., 70, 1916-1924.
71. Below, J.E. et al. (2011) Factors that impact susceptibility to fiber-induced health effects. J. Toxicol. Environ. Health. B. Crit. Rev., 14, 246-266.
72. Carbone, M. et al. (2007) A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat. Rev. Cancer, 7, 147-154.
73. Sugarbaker, D.J. et al. (2008) Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc. Natl Acad. Sci. USA, 105, 3521-3526.